Following a full submission
AWMSG advice |
|||
| Status: Recommended with restrictions | |||
Valganciclovir (Valcyte®) powder for oral solution is recommended as an option for restricted use within NHS Wales for 200 days prophylaxis of cytomegalovirus (CMV) disease in CMV-negative kidney transplant patients who have received a transplant from a CMV-positive donor. Valganciclovir (Valcyte®) powder for oral solution is restricted for use in patients who cannot take tablets or with a CrCl<10 (ml/min). AWMSG is of the opinion that valganciclovir (Valcyte®) powder for oral solution is not suitable for shared care within NHS Wales for the above indication. |
|||
|
|||
Medicine details |
|||
| Medicine name | valganciclovir (Valcyte®) | ||
| Formulation | 50 mg/ml powder for oral solution | ||
| Reference number | 824 | ||
| Indication | Licence extension for 200 days prophylaxis of cytomegalovirus (CMV) disease in CMV-negative kidney transplant patients who have received a transplant from a CMV-positive donor |
||
| Company | Roche Products Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Full | ||
| Status | Recommended with restrictions | ||
| Advice number | 0711 | ||
| NMG meeting date | 11/05/2011 | ||
| AWMSG meeting date | 15/06/2011 | ||
| Ratification by Welsh Government | 01/09/2011 | ||
| Date of issue | 07/09/2011 | ||